Skip to content

Sildenafil Citrate versus Nifedipine in Women with Recurrent Miscarriages: A Pilot Study

Sildenafil Citrate versus Nifedipine in Women with Recurrent Miscarriages: A Pilot Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201710002662398
Enrollment
60
Registered
2017-10-03
Start date
2016-10-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Fertility-female recurrent abortion

Interventions

Nifedipine
sildenafil
control

Sponsors

Menoufia university hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Unexplained recurrent miscarriages of three times or more fathered by the same husband (proved by laboratory documents). Having no living children. range (18 ¿ 35) years. 4. Having had regular menstrual cycles in the three months preceding enrollment. 5. Using neither hormonal contraception nor an intrauterine device.

Exclusion criteria

Exclusion criteria: Women having anatomical uterine abnormalities such as septate uterus, 3rd degree RVF or pathological uterine abnormalities such as myoma or endometrioma on transvaginal ultrasonography. 2. Systemic diseases that may affect hemodynamic indices. 3. A history of oophorectomy or tubal ligation. 4. The presence of side effects or contraindications to both nifedipine and sildenafil citrate. 5. The occurrence of pregnancy during the first study cycle.

Design outcomes

Primary

MeasureTime frame
uterine artery blood flow changes and endometrial thickness following the intake of medications.

Secondary

MeasureTime frame
medication side effects.

Countries

Egypt

Contacts

Public ContactNabih Elkhouly

obstetrics and gynecology department, faculty of medicine Menoufia university

nabih.elkhouly@yahoo.com01060868443

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026